SG11202105279SA - Methods of treating myeloproliferative disorders - Google Patents

Methods of treating myeloproliferative disorders

Info

Publication number
SG11202105279SA
SG11202105279SA SG11202105279SA SG11202105279SA SG11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA
Authority
SG
Singapore
Prior art keywords
methods
myeloproliferative disorders
treating myeloproliferative
treating
disorders
Prior art date
Application number
SG11202105279SA
Other languages
English (en)
Inventor
Adrian Senderowicz
Michael Cooper
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of SG11202105279SA publication Critical patent/SG11202105279SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202105279SA 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders SG11202105279SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/062534 WO2020112086A1 (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
SG11202105279SA true SG11202105279SA (en) 2021-06-29

Family

ID=64734125

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105279SA SG11202105279SA (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Country Status (8)

Country Link
JP (2) JP7453230B2 (enrdf_load_stackoverflow)
KR (2) KR20250004357A (enrdf_load_stackoverflow)
AU (1) AU2018451360B2 (enrdf_load_stackoverflow)
BR (1) BR112021010134A2 (enrdf_load_stackoverflow)
CA (1) CA3120973A1 (enrdf_load_stackoverflow)
EA (1) EA202191489A1 (enrdf_load_stackoverflow)
SG (1) SG11202105279SA (enrdf_load_stackoverflow)
WO (1) WO2020112086A1 (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112939A1 (en) 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
AU2020356575A1 (en) 2019-09-27 2022-04-14 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
MX2022014254A (es) 2020-05-13 2023-02-16 Disc Medicine Inc Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis.
KR20230048042A (ko) * 2020-08-04 2023-04-10 콘스텔레이션 파마슈티칼스, 인크. 혈소판 증가증의 치료를 위한 2-((4s)-6-(4-클로로페닐)-1-메틸-4h-벤조[c]이속사졸로[4,5-e]아제핀-4-일)아세트아미드

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
PL3157928T3 (pl) 2014-06-20 2019-07-31 Constellation Pharmaceuticals, Inc. Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu

Also Published As

Publication number Publication date
JP2022519425A (ja) 2022-03-24
BR112021010134A2 (pt) 2021-08-24
AU2018451360B2 (en) 2022-05-26
KR20210095904A (ko) 2021-08-03
AU2018451360A1 (en) 2021-06-10
EA202191489A1 (ru) 2021-09-10
JP2024063214A (ja) 2024-05-10
WO2020112086A1 (en) 2020-06-04
CA3120973A1 (en) 2020-06-04
JP7453230B2 (ja) 2024-03-19
KR102738936B1 (ko) 2024-12-06
KR20250004357A (ko) 2025-01-07

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL273693A (en) Treatment of inflammatory disorders
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
IL267818A (en) Methods for treating neurological disorders
IL281736A (en) Methods for treating myeloproliferative diseases
IL267229A (en) Methods of treating ocular disorders
ZA202002066B (en) Compositions and methods for the treatment of eye disorders
IL275654B2 (en) Methods for treating castor-related disorders
IL269604A (en) Pentides for the treatment of autoimmune diseases
SG11202105279SA (en) Methods of treating myeloproliferative disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
LT3458067T (lt) Neurologinių sutrikimų gydymas
SG11202102982QA (en) Methods of treating myeloproliferative disorders
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
ZA202002910B (en) Treatment of skin disorders
GB201918853D0 (en) Methods of treatment
IL290983A (en) Treatment methods
HK40055553A (zh) 治疗骨髓增生性病症的方法
HK40052689A (en) Methods of treating myeloproliferative disorders
GB201604359D0 (en) Treatment of tissue disorders
IL268504A (en) Methods of treating seizure disorders
GB2580145B (en) Treatment of produced hydrocarbons
GB2580157B (en) Treatment of produced hydrocarbons
SG11202007642RA (en) Treatment of disorders with tasimelteon